一位医生的坚持揭示了一项关键肾脏病学研究中的问题。

A physician's perseverance uncovers problems in a key nephrology study.

出版信息

Kidney Int. 2012 Jul;82(2):135-7. doi: 10.1038/ki.2012.122.

DOI:10.1038/ki.2012.122

Abstract

The Normal Hematocrit Cardiac Trial, published in 1998, was a foundational study testing erythropoietin analog treatment to normal hematocrit targets. It served as a warning that erythropoietin replacement was not a panacea. Its large size gave it disproportionate weighting in evidence reviews and guideline development and thereby impacted treatment decisions. Coyne shows that the published results did not completely and clearly represent the study's actual results. We discuss the implications and make recommendations to prevent such occurrences.

摘要

《正常血细胞比容心脏试验》发表于 1998 年，是一项基础性研究，旨在测试促红细胞生成素类似物治疗正常血细胞比容目标。该研究警示人们，红细胞生成素替代治疗并非万无一失。由于其规模庞大，在证据综述和指南制定中权重过高，从而影响了治疗决策。 Coyne 表明，已发表的结果并未完全和清晰地代表研究的实际结果。我们讨论了其影响并提出了建议，以防止此类情况再次发生。